Trial
NCT03776864
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Washington
Collaborators
TG Therapeutics, Inc.
Condition
Hodgkin's Lymphoma
Intervention
Pembrolizumab
Why stopped
Company providing drug terminated their oncology program
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-03